[PDF][PDF] Phase II study of gefitinib readministration in patients with advanced
H Asahina, S Oizumi, A Inoue, I Kinoshita, T Ishida… - scholar.archive.org
Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …
conducted the first prospective phase II study of gefitinib readministration in previous …
Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer
J Pan, M Shi, J Feng - 2012 International Conference on …, 2012 - ieeexplore.ieee.org
Patients with advanced or metastatic non-small cell lung cancer (NSCLC) may get benefit
from epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) but eventually …
from epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) but eventually …
[HTML][HTML] Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung …
F Wang, G Guo, H Qiu, W He, F Zhou… - Cancer Biology & …, 2012 - ncbi.nlm.nih.gov
Objective The standard therapy after failure of the initial non-first line epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung …
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung …
[PDF][PDF] Successful rechallenge with gefitinib for an initial erlotinib-responder with advanced lung adenocarcinoma
SC Hong, YS Sim, JH Lee, YJ Ryu… - Tuberculosis and …, 2011 - synapse.koreamed.org
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is
generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of …
generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of …
A case of focal reexpansion pulmonary edema after conventional thoracentesis of pleural effusion
SS Dong, YJ Hong, CC Woong… - Tuberculosis and …, 2004 - khu.elsevierpure.com
A 60-year old male patient admitted with complaints of dyspnea and pleuritic chest pain. The
chest X-ray demonstrated right pleural effusion. We planed to do the conventional …
chest X-ray demonstrated right pleural effusion. We planed to do the conventional …
進行・再発非小細胞肺癌でgefitinib 投与終了翌日よりerlotinib に切り替えた17 例の検討
森川慶， 千場博， 藤井慎嗣， 右山洋平， 入來豊久… - 肺癌, 2012 - jstage.jst.go.jp
抄録 背景. 進行再発非小細胞肺癌に対して, gefitinib 耐性後 erlotinib 投与の病勢制御率は 30%
程度と考えられているが, その適応など一定のコンセンサスは未だ得られていない. 我々は gefitinib …
程度と考えられているが, その適応など一定のコンセンサスは未だ得られていない. 我々は gefitinib …